Acadian Asset Management
AGRX

Acadian Asset Management’s Agile Therapeutics AGRX Stock Holding History

Acadian Asset Management’s Portfolio AGRX Stock Details AGRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q4 		– Sell
-216
Closed -$511K – 2116
2019
Q3 		$511K Sell
216
-9
-4% -$22.2K ﹤0.01% 1079
2019
Q2 		$657K Buy
225
+16
+8% +$44.7K ﹤0.01% 928
2019
Q1 		$630K Buy
209
+52
+33% +$110K ﹤0.01% 1042
2018
Q4 		$180K Buy
157
+114
+265% +$175K ﹤0.01% 1141
2018
Q3 		$32K Hold
43
– – ﹤0.01% 1452
2018
Q2 		$43K Buy
43
+38
+760% +$133K ﹤0.01% 1419
2018
Q1 		$24K Buy
+5
New +$33.1K ﹤0.01% 1470
2017
Q4 		– Sell
-6
Closed -$57K – 1703
2017
Q3 		$57K Buy
+6
New +$46.1K ﹤0.01% 1091

Other funds holding AGRX

PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
IA
Investor AB Stockholm, Sweden $15.1B AUM 29.02% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
EP
Eversept Partners New York $1.9B AUM 121.13% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
SSA
Schonfeld Strategic Advisors New York $14.2B AUM 37.17% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Royal Bank of Canada
Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return
EI
EAM Investors Solana Beach, California $866M AUM 377.14% 1-Year Est. Return

Acadian Asset Management's AGRX Position: Q4 2019 in Review

Acadian Asset Management sold out of Agile Therapeutics (AGRX) in Q4 2019, closing a stake of 216 shares — an estimated $511K sold.

Acadian Asset Management first reported a position in AGRX in Q3 2017 and held it in 8 quarters. The position peaked at $657K in Q2 2019. 46 funds tracked by Wall St. Rank hold AGRX as of Q4 2019.

  • Acadian Asset Management reported no remaining Agile Therapeutics position as of Q4 2019 after selling out during the quarter.
  • Acadian Asset Management sold 216 Agile Therapeutics shares in Q4 2019, an estimated $511K.
  • Acadian Asset Management first reported a position in Agile Therapeutics in Q3 2017 and held it in 8 quarters.
  • Acadian Asset Management's Agile Therapeutics position peaked at $657K in Q2 2019.
  • 46 funds tracked by Wall St. Rank held Agile Therapeutics as of Q4 2019.

Based on Acadian Asset Management's 13F filing for Q4 2019, filed 6 Feb 2020.